Literature DB >> 1827481

Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta.

M J Smyth1, S L Strobl, H A Young, J R Ortaldo, A C Ochoa.   

Abstract

The effect of transforming growth factor-beta 1 (TGF-beta) on activation-induced CD8+ T cell cytotoxicity and gene expression was investigated. TGF-beta was demonstrated to inhibit pore-forming protein (PFP) mRNA expression and total benzoyloxycarbonyl-L-lysine thiobenzyl ester esterase activity in CD8+ T cells cultured with IL-2 and OKT3 mAb for 6 to 18 days. Consistently, in the absence or presence of TGF-beta, the PFP mRNA expression and lymphokine-activated killer (LAK) activity of CD8+ T cells were closely correlated. The inhibitory effects of TGF-beta on both CD8+ T cell PFP mRNA expression and LAK activity were reversible by removal of TGF-beta from the culture. Expression of lymphokines, adhesion/recognition molecules, and activated p55 IL-2R, previously implicated in the lytic mechanism of cytotoxic lymphocytes, either was not detectable or did not correlate with TGF-beta inhibition of LAK activity. In addition, independently of effector/target cell binding, the lectin- or heteroconjugated antibody-dependent cellular cytotoxicity of IL-2/OKT3 mAb-activated CD8+ T cells was inhibited by preculture with TGF-beta. TGF-beta also inhibited the rapid activation-induced expression of PFP mRNA and cytotoxic potential in resting T cells, thereby indicating that the effect of TGF-beta was independent of T cell proliferation. TGF-beta inhibition of CD8+ T cell PFP mRNA expression and cytotoxic potential was TGF-beta dose dependent; however, a variety of activation stimuli (including IL-2, IL-6, and OKT3 mAb) were all similarly inhibited by TGF-beta. Therefore, TGF-beta may be an important general regulator of CD8+ T cell cytotoxic function, in particular by suppressing expression of PFP, a major cytolytic protein implicated in the lytic function of cytotoxic lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827481

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

Review 1.  The transcriptional control of the perforin locus.

Authors:  Matthew E Pipkin; Anjana Rao; Mathias G Lichtenheld
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

Review 2.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

3.  Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta.

Authors:  M R Young; M A Wright; M Coogan; M E Young; J Bagash
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 4.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

Review 5.  Mechanisms of self-nonself discrimination and possible clinical relevance.

Authors:  Carolin Daniel; Jens Nolting; Harald von Boehmer
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

6.  Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.

Authors:  Richard C Wu; Shujuan Liu; Jessica A Chacon; Sheng Wu; Yufeng Li; Pariya Sukhumalchandra; James L Murray; Jeffrey J Molldrem; Patrick Hwu; Hanspeter Pircher; Gregory Lizée; Laszlo G Radvanyi
Journal:  Clin Cancer Res       Date:  2012-02-03       Impact factor: 12.531

7.  Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta.

Authors:  Laurent-Olivier Roy; Marie-Belle Poirier; David Fortin
Journal:  Invest New Drugs       Date:  2015-08-15       Impact factor: 3.850

8.  Fascin-1 knock-down of human glioma cells reduces their microvilli/filopodia while improving their susceptibility to lymphocyte-mediated cytotoxicity.

Authors:  Neil T Hoa; Lisheng Ge; Kate L Erickson; Carol A Kruse; Andrew N Cornforth; Yurii Kuznetsov; Alex McPherson; Filippo Martini; Martin R Jadus
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

9.  Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo.

Authors:  David A Horwitz; Stephanie Pan; Jing-Ni Ou; Julie Wang; Maogen Chen; J Dixon Gray; Song Guo Zheng
Journal:  Clin Immunol       Date:  2013-08-20       Impact factor: 3.969

Review 10.  Transforming growth factor beta (TGF-beta) and inflammation in cancer.

Authors:  Brian Bierie; Harold L Moses
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.